STERIS plc

STERIS plc

STE·NYSE

$213.57

+1.8%
HealthcareMedical - Devices

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

At a Glance

Live Snapshot
Market Cap$20.85B
EPS7.9300
P/E Ratio26.93
Earnings Date08/05/2026
8.47%
Return on Invested Capital
18%
3Y+32.0%
5Y+21.0%
10Y+184.0%
10.93%
Return on Equity
17%
3Y+521.0%
5Y+7.0%
10Y+178.0%
7.31%
Return on Assets
21%
3Y+639.0%
5Y+21.0%
10Y+227.0%
STERIS plc

STERIS plc Management Team

STE · NYSE
DA

Daniel A. Carestio

President, Chief Executive Officer & Director

Compensation

$2,284,218

Born 1973(Age 53)
male
MC

Mary Clare Fraser

SVP & Chief Human Resources Officer

Compensation

$725,668

Born 1970(Age 56)
female
KE

Kenneth E. Kohler

Senior Vice President & GM of AST

Born 1963(Age 63)
male
AX

Andrew Xilas

Senior Vice President & GM of Dental

Compensation

$1,438,246

Born 1965(Age 61)
male
JK

Julia K. Madsen

Senior Vice President & GM of Life Sciences

Born 1965(Age 61)
female
CL

Cary L. Majors

Senior Vice President & President of Healthcare

Compensation

$861,813

Born 1975(Age 51)
male
KL

Karen L. Burton

Senior Vice President, Chief Financial Officer & Chief Accounting Officer

Born 1968(Age 58)
female
JA

John Adam Zangerle

Senior Vice President, General Counsel & Secretary

Compensation

$943,792

Born 1967(Age 59)
male
LM

Lindsey McGowan

VP, Chief Compliance & Quality Officer

female
JW

Julie Winter

Vice President of Investor Relations & Corporate Communications

female
ste

STERIS plc Insider Positioning

STE · NYSE

During the last 12 months, insiders have sold $2.15M worth of STE shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

3.1K

734.88K

Net Activity

-735K

-$735K

6-9 Months

Bought

0

0.00

Sold

5.5K

1.42M

Net Activity

-1.4M

-$1.42M

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

1
TR

Tamaro Renato

Officer: V.P. & Corporate Treasurer

3.3K shares1 transactions

$856K

2
FCL

Feldmann Cynthia L

Director

3.1K shares1 transactions

$735K

3
MJ

Madsen Julia

Officer: Sr. Vp And Gm, Life Sciences

2.1K shares1 transactions

$560K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $2.15M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Insider Participation

High Selling

3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

SEC Filings

STE - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

June 12, 2025
July 31, 2025
2025
DEF 14A

DEF 14A 2024

N/A

June 12, 2024
August 01, 2024
2024
DEF 14A

DEF 14A

N/A

June 07, 2023
June 07, 2023
 
DEF 14A

DEF 14A 2022

N/A

June 07, 2022
July 28, 2022
2022
DEF 14A

DEF 14A 2021

N/A

June 07, 2021
July 29, 2021
2021
DEF 14A

DEF 14A 2020

N/A

June 05, 2020
July 28, 2020
2020
DEF 14A

DEF 14A 2019

N/A

June 05, 2019
July 30, 2019
2019
Showing 1 to 7 of 7 filings